Aptose Biosciences Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Note 1 - Reporting Entity

Note 1 - Reporting Entity	12 Months Ended
Dec. 31, 2025
Disclosure Text Block [Abstract]
Reporting entity	1. Reporting entity Aptose Biosciences Inc. (“Aptose” or the "Company") is a science-driven, clinical-stage biotechnology company committed to the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company’s executive offices are located in San Diego, California, and its head office address is located at 66 Wellington Street West, Suite 5300, TD Bank Tower, Box 48, Toronto, Ontario, Canada. The Company is advancing targeted agents to treat life-threatening hematologic cancers that require immediate treatment. The Company has one clinical-stage oral kinase inhibitor under active development for the treatment of hematological malignancies: tuspetinib.

Note 1 - Reporting Entity

12 Months Ended

Dec. 31, 2025

Aptose Biosciences Inc. (“Aptose” or the "Company") is a science-driven, clinical-stage biotechnology company committed to the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company’s executive offices are located in San Diego, California, and its head office address is located at 66 Wellington Street West, Suite 5300, TD Bank Tower, Box 48, Toronto, Ontario, Canada.

The Company is advancing targeted agents to treat life-threatening hematologic cancers that require immediate treatment. The Company has one clinical-stage oral kinase inhibitor under active development for the treatment of hematological malignancies: tuspetinib.